🇺🇸 Tacrolimus modified-release in United States

7 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Window: 23 April 2025 – 23 April 2026
Total reports: 7

Most-reported reactions

Aplasia Pure Red Cell — 1 report (14.29%)
Escherichia Urinary Tract Infection — 1 report (14.29%)
Herpes Zoster — 1 report (14.29%)
Parvovirus B19 Infection — 1 report (14.29%)
Pneumonia — 1 report (14.29%)
Tinea Infection — 1 report (14.29%)
Wound Infection — 1 report (14.29%)

Source database →

Other Immunology approved in United States

Frequently asked questions

Is Tacrolimus modified-release approved in United States?

Tacrolimus modified-release does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Tacrolimus modified-release in United States?

Hospital de Clinicas de Porto Alegre is the originator. The local marketing authorisation holder may differ — check the official source linked above.